Back to results
US 9,005,599 B2Granted
Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
AssigneeTissue Regeneration Therapeutics Inc.
InventorsJane Elizabeth Ennis, Jeffrey Donald Turner, John Edward Davies
Life of this patent
Estimating the term…
Abstract
The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord perivascular cells.
Claims16
A method for treating or protecting a human subject exposed to a chemical agent comprising administering to the subject a composition comprising an isolated cell population comprising human umbilical cord perivascular cells (HUCPVCs) having a 3G5+, CD45−, CD44+ phenotype,
- wherein the cell population is characterized by rapid proliferation and the presence of human progenitor cells, and the HUCPVCs in said cell population are genetically modified to express a butyrylcholinesterase (BChE) polypeptide or to increase the expression of an endogenous butyrylcholinesterase (BChE) polypeptide, and
- wherein said composition treats or protects said subject exposed to said chemical agent.
Dependencies are inferred from the claim text.